246 related articles for article (PubMed ID: 11005706)
21. Classification of drugs for teratogenic risk: an anachronistic way of counseling: a reply to Merlob And Stahl.
Briggs GG; Freeman RK; Yaffe SJ
Birth Defects Res A Clin Mol Teratol; 2003 Mar; 67(3):207-8. PubMed ID: 12797465
[No Abstract] [Full Text] [Related]
22. Drug use during pregnancy: are risk classifications more dangerous than the drugs?
Bianca S
Lancet; 2003 Jul; 362(9380):329. PubMed ID: 12892970
[No Abstract] [Full Text] [Related]
23. Maternal characteristics associated with pregnancy exposure to FDA category C, D, and X drugs in a Canadian population.
Yang T; Walker MC; Krewski D; Yang Q; Nimrod C; Garner P; Fraser W; Olatunbosun O; Wen SW
Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):270-7. PubMed ID: 18181228
[TBL] [Abstract][Full Text] [Related]
24. The critical need for clinical decision support systems for identification and management of teratogenic medications.
DiPietro Mager NA
J Am Pharm Assoc (2003); 2019; 59(2S):S18-S20. PubMed ID: 30737104
[TBL] [Abstract][Full Text] [Related]
25. Adaptation for Regulatory Application: A Content Analysis of FDA Risk Evaluation and Mitigation Strategies Assessment Plans (2014-2018) Using RE-AIM.
Toyserkani GA; Huynh L; Morrato EH
Front Public Health; 2020; 8():43. PubMed ID: 32158741
[No Abstract] [Full Text] [Related]
26. [An update in drug use during pregnancy: risk classification].
Gallego Úbeda M; Delgado Téllez de Cepeda L; Campos Fernández de Sevilla Mde L; De Lorenzo Pinto A; Tutau Gómez F
Farm Hosp; 2014 Jul; 38(4):364-78. PubMed ID: 25137169
[TBL] [Abstract][Full Text] [Related]
27. Drugs in pregnancy.
Koren G; Pastuszak A; Ito S
N Engl J Med; 1998 Apr; 338(16):1128-37. PubMed ID: 9545362
[No Abstract] [Full Text] [Related]
28. FDA-approved drug labeling for the study of drug-induced liver injury.
Chen M; Vijay V; Shi Q; Liu Z; Fang H; Tong W
Drug Discov Today; 2011 Aug; 16(15-16):697-703. PubMed ID: 21624500
[TBL] [Abstract][Full Text] [Related]
29. Quantitative structure-activity relationship models for predicting drug-induced liver injury based on FDA-approved drug labeling annotation and using a large collection of drugs.
Chen M; Hong H; Fang H; Kelly R; Zhou G; Borlak J; Tong W
Toxicol Sci; 2013 Nov; 136(1):242-9. PubMed ID: 23997115
[TBL] [Abstract][Full Text] [Related]
30. Advice on drug safety in pregnancy: are there differences between commonly used sources of information?
Frost Widnes SK; Schjøtt J
Drug Saf; 2008; 31(9):799-806. PubMed ID: 18707194
[TBL] [Abstract][Full Text] [Related]
31. Prescription medications for use in pregnancy-perspective from the US Food and Drug Administration.
Wesley BD; Sewell CA; Chang CY; Hatfield KP; Nguyen CP
Am J Obstet Gynecol; 2021 Jul; 225(1):21-32. PubMed ID: 34215352
[TBL] [Abstract][Full Text] [Related]
32. Categorizing the safety of medications during pregnancy and lactation.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2009 Apr; 47(4):17-20. PubMed ID: 19437927
[TBL] [Abstract][Full Text] [Related]
33. Systematic procedure for the classification of proven and potential teratogens for use in research.
Eltonsy S; Martin B; Ferreira E; Blais L
Birth Defects Res A Clin Mol Teratol; 2016 Apr; 106(4):285-97. PubMed ID: 26969841
[TBL] [Abstract][Full Text] [Related]
34. Assessment of YouTube videos as a source of information on medication use in pregnancy.
Hansen C; Interrante JD; Ailes EC; Frey MT; Broussard CS; Godoshian VJ; Lewis C; Polen KN; Garcia AP; Gilboa SM
Pharmacoepidemiol Drug Saf; 2016 Jan; 25(1):35-44. PubMed ID: 26541372
[TBL] [Abstract][Full Text] [Related]
35. Prescription drug use in pregnancy: a retrospective, population-based study in British Columbia, Canada (2001-2006).
Daw JR; Mintzes B; Law MR; Hanley GE; Morgan SG
Clin Ther; 2012 Jan; 34(1):239-249.e2. PubMed ID: 22169049
[TBL] [Abstract][Full Text] [Related]
36. Recent changes in pregnancy and lactation labeling: retirement of risk categories.
Ramoz LL; Patel-Shori NM
Pharmacotherapy; 2014; 34(4):389-95. PubMed ID: 24390829
[TBL] [Abstract][Full Text] [Related]
37. Drug use by pregnant women and comparable non-pregnant women in The Netherlands with reference to the Australian classification system.
Schirm E; Meijer WM; Tobi H; de Jong-van den Berg LT
Eur J Obstet Gynecol Reprod Biol; 2004 Jun; 114(2):182-8. PubMed ID: 15140513
[TBL] [Abstract][Full Text] [Related]
38. Human teratogens: update 2010.
Holmes LB
Birth Defects Res A Clin Mol Teratol; 2011 Jan; 91(1):1-7. PubMed ID: 21254353
[TBL] [Abstract][Full Text] [Related]
39. Review of embryo-fetal developmental toxicity studies performed for pharmaceuticals approved by FDA in 2016 and 2017.
Barrow P
Reprod Toxicol; 2018 Sep; 80():117-125. PubMed ID: 29660390
[TBL] [Abstract][Full Text] [Related]
40. Survey of safety and efficacy information in drug inserts for topical prescription medications.
Zaghi D; Maibach HI
Am J Clin Dermatol; 2007; 8(1):43-6. PubMed ID: 17298106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
